DEF: Silexion Therapeutics Seeks Shareholder Approval for Key Proposals

Silexion Therapeutics Corp. is holding an extraordinary general meeting on April 28, 2026, to seek shareholder approval for proposals including an increase in authorized share capital, an amendment to its equity incentive plan, and a reverse stock split.

Summary

• Silexion Therapeutics Corp. is convening an extraordinary general meeting on April 28, 2026, to vote on three critical proposals.
• Proposal 1: Increase authorized share capital by 50,000,000 ordinary shares, from 9,000,000 to 59,000,000 shares, to maintain Nasdaq listing compliance and fund operations.
• Proposal 2: Amend the 2024 Equity Incentive Plan to increase the annual share pool addition from 5% to a level that maintains an aggregate of 10% of issued and outstanding shares on a fully diluted basis.
• Proposal 3: Authorize the Board of Directors to implement a reverse stock split of ordinary shares at a ratio between 1-for-4 and 1-for-10 to comply with Nasdaq's minimum bid price requirement.
• The company states that the increase in authorized share capital is crucial for maintaining its Nasdaq Capital Market listing, which requires a minimum of $2.5 million in shareholder equity.
• The reverse stock split is intended to ensure the ordinary shares maintain a minimum bid price of $1.00 per share, a requirement for continued listing on Nasdaq.
• Shareholders of record as of April 7, 2026, are entitled to vote at the meeting.
• The Board of Directors unanimously recommends a vote FOR all three proposals.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative. While the company is taking proactive steps to maintain its Nasdaq listing and fund operations, the proposals themselves (capital increase and reverse split) highlight existing financial pressures and potential shareholder dilution, which are significant concerns.

Positives

• The company is proactively addressing Nasdaq listing requirements, aiming to maintain its listing on the Nasdaq Capital Market.
• The proposed increase in authorized share capital and reverse stock split are designed to support future financing activities and operational needs.
• The amendment to the equity incentive plan aims to attract and retain key talent, aligning employee interests with shareholders.
• The company is seeking shareholder approval for these critical measures, demonstrating a commitment to corporate governance.
• The Board of Directors unanimously recommends approval of all proposals, indicating strong internal support.

Negatives

• The company has previously failed to comply with the minimum bid price requirement and had to implement a reverse stock split.
• The proposed increase in authorized share capital, if approved and utilized, could lead to substantial dilution for existing shareholders.
• The reverse stock split may negatively impact the market for ordinary shares and potentially increase price volatility.
• The company acknowledges that the anticipation of future share issuances could make it more difficult to sell equity securities at favorable prices.
• There is a risk that the market capitalization may not increase proportionally after the reverse stock split.

Risks

• Dilution to existing shareholders due to the potential issuance of a substantial number of additional ordinary shares.
• A decline in the trading price of ordinary shares, potentially jeopardizing compliance with Nasdaq's minimum bid price requirement.
• Increased share price volatility and potential difficulty in trading odd lots after a reverse stock split.
• The potential for the authorized but unissued shares to be used to resist or frustrate a third-party takeover attempt.
• The risk that the reverse stock split may not successfully increase or sustain the share price, or that liquidity may be adversely affected.
• The possibility of delisting from Nasdaq if compliance with listing standards is not maintained, despite these proposed actions.

Future Outlook

The company is seeking shareholder approval for proposals that are critical for its continued listing on the Nasdaq Capital Market, funding its clinical development programs for RNAi therapies, and attracting/retaining talent. The success of these proposals is essential for the company's near-to-mid-term operational goals and value creation for shareholders. The company anticipates pursuing financing transactions, potentially including public offerings and ATM programs, and business development opportunities.

Management Comments

• "Our Nasdaq listing is a critical asset of our company and our shareholders, as it enhances the price and liquidity of, and the trading market for, our securities, and it is therefore in the best interest of our shareholders that we preserve it."
• "As we navigate the upcoming critical period in the clinical development of our innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, we will need both sufficient funding and transactional flexibility for that development process."
• "We seek to proactively protect our Nasdaq listing, which we consider a critical asset of our company, and to preempt any potential deficiency as to the minimum bid price requirement."
• "Equity compensation is a vital component of our overall compensation strategy."
• "The Board believes that the proposed alternate evergreen provision is necessary to retain our companys human talent at this critical stage of our development and support our long-term growth and the advancement of our RNAi therapies, especially given the competitive landscape in the biotechnology sector."

Industry Context

StockSavvy.ai notes that Silexion Therapeutics operates in the highly competitive biotechnology sector, where maintaining Nasdaq listing and securing adequate funding for clinical development are paramount. The proposed actions, including capital increases and reverse stock splits, are common strategies employed by clinical-stage biotech companies facing similar challenges in meeting listing requirements and attracting investment.

Comparison to Industry Standards

• The proposed equity incentive plan amendment aims to reserve up to 10% of issued and outstanding shares on a fully diluted basis, which aligns with the recommended limit for equity incentive dilution supported by institutional shareholder groups like ISS and Glass Lewis.
• The company's reliance on equity financings (public offerings, ATM programs) for funding clinical development is a standard practice within the biotechnology industry, where R&D costs are high and profitability is often distant.
• The need for a reverse stock split to maintain a minimum bid price is a frequent occurrence for small-cap companies, particularly in the biotech sector, to avoid delisting from exchanges like Nasdaq.

Related Party Transactions

• The Moringa sponsor promissory note is held by Moringa Sponsor, LP and related persons, with Ilan Levin identified as having sole voting and investment authority. The note has $1,633,000 remaining outstanding and can be converted into ordinary shares.

Stakeholder Impact

• Shareholders: Potential dilution from future share issuances, potential increase in share price due to reverse split, but also risk of price decline and delisting. Their voting rights are crucial for the proposed changes.
• Employees, Officers, and Directors: The equity incentive plan amendment aims to provide competitive compensation, aligning their interests with shareholders.
• Creditors: The conversion of the Moringa sponsor promissory note could impact outstanding debt.
• Nasdaq: The company is actively working to comply with Nasdaq's listing rules to maintain its listing.

Next Steps

• Shareholders to vote on the three proposals at the Extraordinary General Meeting on April 28, 2026.
• If approved, the Board of Directors will implement the increase in authorized share capital and potentially the reverse stock split.
• The company plans to pursue financing transactions and business development opportunities utilizing the increased authorized capital.
• The company will continue to advance its SIL-204B platform product through clinical development.

Key Dates

Recommendation

Keywords

Silexion Therapeutics, DEF 14A, Proxy Statement, Share Capital Increase, Equity Incentive Plan, Reverse Stock Split, Nasdaq Compliance, Shareholder Meeting, Biotechnology, RNAi Therapies